{"id":30555,"date":"2025-03-26T14:59:19","date_gmt":"2025-03-26T06:59:19","guid":{"rendered":"https:\/\/flcube.com\/?p=30555"},"modified":"2025-03-26T14:59:21","modified_gmt":"2025-03-26T06:59:21","slug":"alphamab-oncology-reports-192-58-revenue-surge-led-by-envafolimab","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30555","title":{"rendered":"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab"},"content":{"rendered":"\n

Alphamab Oncology (HKG: 9966<\/a>) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core product envafolimab (KN035) and licensing fee income.<\/p>\n\n\n\n

Financial Highlights<\/strong>
Research and development expenses remained stable at RMB 404.15 million (USD 55.6 million), reflecting strategic investment in innovation. As of December 31, 2024, the company’s cash reserves stood at RMB 1,571.47 million (USD 216.3 million), providing a strong foundation for future growth.<\/p>\n\n\n\n

Core Product Performance<\/strong>
Envafolimab, the world’s first and currently only PD-L1 single-domain antibody and human IgG1 Fc fusion protein, continues to drive commercial success. Co-developed with 3D Medicines (HKG: 1244<\/a>), the drug received approval in mainland China and Macau in 2021 and January 2024, respectively. Alphamab also secured a licensing deal with Glenmark Pharmaceuticals, granting exclusive rights to develop and commercialize the drug in multiple regions including India, Asia Pacific (excluding Singapore, Thailand, Malaysia), the Middle East, Africa, Russia, CIS, and Latin America.<\/p>\n\n\n\n

Pipeline Progress<\/strong>
Alphamab’s innovative pipeline advanced significantly in 2024. KN026 (HER2 heterodimer bispecific antibody), JSKN003 (HER2 bispecific antibody drug conjugate), JSKN016 (HER3 \u00d7 TROP2 bispecific ADC), and KN046 (CTLA-4 \u00d7 PD-L1 BsAb) all entered clinical development, underscoring the company’s commitment to advancing oncology treatments.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with…<\/p>\n","protected":false},"author":1,"featured_media":30556,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[605,187,30,27,894,854],"class_list":["post-30555","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-3d-medicines","tag-alphamab-oncology","tag-biotech","tag-finanical-reports","tag-hkg-1244","tag-hkg-9966"],"yoast_head":"\nAlphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core product envafolimab (KN035) and licensing fee income.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30555\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core product envafolimab (KN035) and licensing fee income.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30555\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T06:59:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T06:59:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2610-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab\",\"datePublished\":\"2025-03-26T06:59:19+00:00\",\"dateModified\":\"2025-03-26T06:59:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2610-png.webp\",\"keywords\":[\"3D Medicines\",\"Alphamab Oncology\",\"Biotech\",\"Finanical Reports\",\"HKG: 1244\",\"HKG: 9966\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30555#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30555\",\"name\":\"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2610-png.webp\",\"datePublished\":\"2025-03-26T06:59:19+00:00\",\"dateModified\":\"2025-03-26T06:59:21+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core product envafolimab (KN035) and licensing fee income.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30555\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2610-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2610-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30555#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab - Insight, China's Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core product envafolimab (KN035) and licensing fee income.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30555","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab","og_description":"Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core product envafolimab (KN035) and licensing fee income.","og_url":"https:\/\/flcube.com\/?p=30555","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-26T06:59:19+00:00","article_modified_time":"2025-03-26T06:59:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2610-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30555#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30555"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab","datePublished":"2025-03-26T06:59:19+00:00","dateModified":"2025-03-26T06:59:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30555"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30555#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2610-png.webp","keywords":["3D Medicines","Alphamab Oncology","Biotech","Finanical Reports","HKG: 1244","HKG: 9966"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30555#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30555","url":"https:\/\/flcube.com\/?p=30555","name":"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30555#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30555#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2610-png.webp","datePublished":"2025-03-26T06:59:19+00:00","dateModified":"2025-03-26T06:59:21+00:00","description":"Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core product envafolimab (KN035) and licensing fee income.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30555#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30555"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30555#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2610-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2610-png.webp","width":1080,"height":608,"caption":"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30555#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2610-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30555"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30555\/revisions"}],"predecessor-version":[{"id":30557,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30555\/revisions\/30557"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30556"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}